Format

Send to:

Choose Destination
See comment in PubMed Commons below
Digestion. 2005;71(1):19-25. Epub 2005 Feb 4.

Severe and steroid-resistant Crohn's disease.

Author information

  • 1Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland. pierre.michetti@chuv.hospvd.ch

Abstract

Patients with moderate to severe disease and patients with steroid-refractory or steroid-dependent disease differ in their management, as the latter groups usually include patients with less acute situations. Systemic corticosteroids represent the mainstay of the management of moderate to severe disease and remain the first-line therapy in this setting. Infliximab is the choice alternative for patients who do not respond to steroids or in whom steroids are contraindicated. Purine analogues, methotrexate and infliximab have shown efficacy in achieving steroid-free remission in patients with steroid-refractory or -dependent disease. Other fast-acting immunosuppressors showed little benefit. Surgery may be indicated in this setting. Nataluzimab may prove useful in patients refractory to infliximab.

Copyright (c) 2005 S. Karger AG, Basel.

PMID:
15711044
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk